For home parenteral nutrition, PICCs should be used for short-term therapy
the ONA take:
According to a new study published in the Journal of Parenteral and Enteral Nutrition (JPEN), researchers at Aalborg University in Aalborg, Denmark, have found that using a peripherally inserted central venous catheter (PICC) for one additional infusion day per week significantly reduced the amount of time before a first bloodstream infection.
For the study, researchers sought to examine whether environmental factors have an influence on the amount of time before a first infection in home parenteral nutrition patients.
Researchers enrolled 136 patients suffering from intestinal failure who were receiving home parenteral nutrition. There was a total of 169 tunneled vascular access devices and 126 PICCs used.
Researchers also found that using a tunneled vascular access device managed by a home care nurse increased the incidence of bloodstream infections.
The authors conclude that the PICCs should only be used for short-term therapy and when few infusion days per week are necessary.
Using a peripherally inserted central venous catheter significantly reduced the amount of time before a first bloodstream infection.
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Immune Thrombocytopenia (Fact Sheet)
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|